Erbitux head/neck cancer sBLA delay
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb and ImClone will delay submission of Erbitux (cetuximab) for head and neck cancer until the end of the year to allow for an independent review of a pivotal Phase III study (IMC-9815). The companies originally planned a second-quarter submission. The delay is needed "to conduct additional and independent analysis of the primary endpoint of...locoregional control," ImClone Chief Medical Officer Eric Rowinsky explained during an April 13 conference call. The trial's secondary endpoint of survival will not be subject to independent review, according to the company...
You may also be interested in...
Erbitux Head And Neck Cancer Application Slated For Third Quarter
Bristol-Myers Squibb and ImClone plan to submit Erbitux for head and neck cancer in the third quarter after an independent review confirmed that a Phase III trial met its primary endpoint
ASCO In Brief
Celgene Revlimid MDS data: Celgene's immunomodulatory drug Revlimid (lenalidomide) achieved a 70% cytogenetic response rate in a pivotal, Phase II trial (MDS-003) including 148 patients with 5q deletion myelodysplastic syndromes, the company reports May 15 at the American Society of Clinical Oncology meeting in Orlando, Fla. The firm notes that 66% of the 146 patients who were transfusion dependent at baseline achieved transfusion independence and a median hemoglobin increase of 5.3 g/dL. Investigators concluded that lenalidomide has "unprecedented hematologic and [cytogenetic] remitting activity." Celgene completed a rolling submission of its Revlimid NDA for MDS patients with the 5q abnormality in March; a priority review is expected...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.